3 web-developer-"https:"-"https:"-"https:" positions at Center for Biologics Evaluation and Research (CBER)

FDA Non-clinical Identification and Mitigation of Safety Risks During the Development and Licensure of Protein-therapeutics

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 20 hours ago

human pathogens are the most extensively studied CRISPR-Cas gene editors.  An important hurdle when developing and licensing a protein for clinical applications is the potential for immune responses

FDA Optimization Modeling to Support Benefit-Risk Assessment Fellowship

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 20 hours ago

products including blood, vaccines, allergenics, tissues, and cellular and gene therapies. Research Project: You will participate in the development of novel quantitative approaches for benefit-risk analyses

FDA Evaluation and Characterization of Neutralizing Antibodies Against Viruses Relevant to Blood-Derived Products

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 20 hours ago

of hepatitis viruses and developing assay protocols to monitor virus-neutralizing activities of immunoglobulin intravenous (IGIV) products. The following articles in the literature provide examples of the range